Anika Therapeutics, Inc.
ANIK
$9.05
$0.688.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.87% | 12.83% | 6.88% | -41.46% | -39.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.87% | 12.83% | 6.88% | -41.46% | -39.36% |
| Cost of Revenue | 175.82% | 121.40% | 87.85% | -19.95% | -54.50% |
| Gross Profit | -32.02% | -31.57% | -29.59% | -54.33% | -30.41% |
| SG&A Expenses | 39.18% | 22.83% | 2.00% | -65.29% | -57.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.29% | 56.96% | 32.91% | -47.99% | -54.76% |
| Operating Income | -348.72% | -367.27% | -1,942.40% | 84.50% | 152.89% |
| Income Before Tax | -334.30% | -346.34% | -1,072.78% | 80.85% | 156.31% |
| Income Tax Expenses | -43.75% | -24.77% | -5.99% | 423.10% | 313.53% |
| Earnings from Continuing Operations | -895.52% | -885.13% | -973.02% | 25.99% | 123.25% |
| Earnings from Discontinued Operations | -18,582.86% | -597.46% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.27% | 26.14% | 31.79% | -296.83% | -234.53% |
| EBIT | -348.72% | -367.27% | -1,942.40% | 84.50% | 152.89% |
| EBITDA | -205.66% | -194.73% | -231.79% | 135.92% | 320.75% |
| EPS Basic | 18.14% | 26.12% | 31.95% | -295.72% | -234.29% |
| Normalized Basic EPS | -299.73% | -305.96% | -787.66% | 92.07% | 167.09% |
| EPS Diluted | 17.87% | 26.04% | 31.97% | -293.24% | -231.06% |
| Normalized Diluted EPS | -299.44% | -305.96% | -787.66% | 92.08% | 167.10% |
| Average Basic Shares Outstanding | -1.40% | -0.33% | 0.43% | 0.59% | 0.42% |
| Average Diluted Shares Outstanding | -1.09% | -0.23% | 0.53% | 0.62% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |